Sector News

Shire anounces director and senior management changes

August 22, 2017
Life sciences

On August 21, 2017, Shire, a biotechnology company focused on developing therapies for rare diseases, announced that chief financial officer (CFO) Jeff Poulton will be leaving the company at the end of the year to serve as CFO at Indigo, a start-up company based in Boston that uses the plant microbiome to improve the productivity and sustainability of agriculture.

Poulton will continue to serve as CFO as the board conducts a formal search for his successor. During this transition period, Poulton will also remain on the company’s executive committee and board of directors, and will continue to support the company’s on-going business review.

“It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company. It has been a difficult decision, but in departing Shire, I wanted to join a smaller organization where I can play a role in building a new company,” said Poulton, in a company press release. “As Shire finalizes the integration of Baxalta and focuses on paying down debt, this also presents a perfect time for me to begin this transition. I know I leave Shire well positioned to pursue its strategy and deliver value for shareholders, supported by a strong Finance team.”

Effective immediately, the company also announced Joanne Cordeiro as their new chief human resources officer and member of the executive committee. She takes over the role previously held by Ginger Gregory. Cordeiro joined Shire in March 2011 and has been serving as interim head of human resources since March 2017.

Source: Shire

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.

Send this to a friend